{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:35:33Z","timestamp":1793140533945,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer US Pharmaceuticals Group grant","award":["53857367"],"award-info":[{"award-number":["53857367"]}]},{"name":"National Cancer Institute , United states","award":["T32CA009515"],"award-info":[{"award-number":["T32CA009515"]}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19IPLOI34760622"],"award-info":[{"award-number":["19IPLOI34760622"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with cancer treated with immune checkpoint inhibitors (ICIs) develop immune related adverse events (irAEs), however biomarkers are lacking. We hypothesized that clinicopathologic and laboratory factors would be associated with irAE risk and overall survival (OS) in this population. In a retrospective study of patients treated with ICIs we collected clinicopathologic, laboratory, irAEs and outcomes data. The association between baseline blood biomarkers, clinicopathologic features and irAEs was assessed by logistic regression adjusting for age, sex, smoking, cancer type, performance status, concomitant other systemic therapy, history of autoimmune disease (AD), chronic infection and pre-existing systemic steroid use (regardless of dose). Optimal cutoff values of biomarkers were identified by recursive partitioning analysis. 470 patients were identified; 156 (33%) developed irAEs, which were associated with baseline absolute lymphocyte count\u2009&gt;\u20092.6\u00a0k\/ul (adjusted [a]OR: 4.30), absolute monocyte count\u2009&gt;\u20090.29\u00a0k\/ul\u00a0(aOR: 2.34) and platelet count\u2009&gt;\u2009145\u00a0k\/ul (aOR: 2.23), neutrophil to lymphocyte ratio (NLR)\u2009\u2264\u20095.3 (aOR: 2.07) and monocyte to lymphocyte ratio (MLR)\u2009\u2264\u20090.73 (aOR: 2.96), as well as platelet to lymphocyte ratio\u2009\u2264\u2009534 (aOR: 5.05). Patients with pre-existing AD (aOR: 2.57), family history of AD (aOR: 5.98), and ICI combination (aOR: 2.00) had higher odds of irAEs. Baseline NLR\u2009\u2264\u20095.3 (aHR: 0.68), MLR\u2009\u2264\u20090.73 (aHR: 0.43), PLT\u2009&gt;\u2009145 (aHR: 0.48) and PLR\u2009\u2264\u2009534 (aHR: 0.48) were associated with longer OS. irAEs were associated with autoimmune history, ICI combination and baseline laboratory measurements. Lower NLR, MLR\u00a0and PLR may have favorable prognostic value. Our hypothesis-generating findings require validation in larger prospective studies.<\/jats:p>","DOI":"10.1038\/s41598-021-88307-3","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T06:13:30Z","timestamp":1619504010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors"],"prefix":"10.1038","volume":"11","author":[{"given":"Despina","family":"Michailidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Diamantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"issue":"6","key":"88307_CR1","doi-asserted-by":"publisher","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","volume":"17","author":"LC Kennedy","year":"2019","unstructured":"Kennedy, L. C. et al. Preexisting autoimmune disease: Implications for immune checkpoint inhibitor therapy in solid tumors. J. Natl. Compr. Canc. Netw. 17(6), 750\u2013757 (2019).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"88307_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A. et al. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"88307_CR3","doi-asserted-by":"crossref","unstructured":"Kumar P, et al. Cancer immunotherapy with checkpoint inhibitor can cause autoimmune adverse events due to loss of\u00a0Treg\u00a0homeostasis. Semin. Cancer Biol. (2019).","DOI":"10.1016\/j.semcancer.2019.01.006"},{"issue":"5","key":"88307_CR4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3747\/co.25.4235","volume":"25","author":"G Myers","year":"2018","unstructured":"Myers, G. Immune-related adverse events of immune checkpoint inhibitors: A brief review. Curr. Oncol. 25(5), 342\u2013347 (2018).","journal-title":"Curr. Oncol."},{"key":"88307_CR5","unstructured":"Wang DY, et al. Fatal toxic effects associated with immune checkpoint inhibitors. A systematic review and meta-analysis. JAMA Oncol. 4(12), 1721\u20131728 (2018)."},{"issue":"Suppl 1","key":"88307_CR6","first-page":"9","volume":"10","author":"B Hoffner","year":"2019","unstructured":"Hoffner, B. et al. Meeting the challenge of immune-related adverse events with optimized telephone triage and dedicated oncology acute care. J. Adv. Pract. Oncol. 10(Suppl 1), 9\u201320 (2019).","journal-title":"J. Adv. Pract. Oncol."},{"issue":"8","key":"88307_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"88307_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16(9), 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"88307_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.immuni.2014.11.005","volume":"41","author":"SL Topalian","year":"2014","unstructured":"Topalian, S. L. et al. Balance and imbalance in the immune system: Life on the edge. Immunity 41, 682\u2013684 (2014).","journal-title":"Immunity"},{"issue":"9","key":"88307_CR10","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.3390\/ijms21093389","volume":"21","author":"K Melissaropoulos","year":"2020","unstructured":"Melissaropoulos, K. et al. Rheumatic manifestations in patients treated with immune checkpoint inhibitors. Int. J. Mol. Sci. 21(9), 3389 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"88307_CR11","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","volume":"69","author":"LC Cappelli","year":"2017","unstructured":"Cappelli, L. C. et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care Res. (Hoboken). 69(11), 1751\u20131763 (2017).","journal-title":"Arthritis Care Res. (Hoboken)."},{"key":"88307_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00281-016-0595-8","volume":"39","author":"M Donia","year":"2017","unstructured":"Donia, M. et al. Cancer immunotherapy in patients with preexisting autoimmune disorders. Semin. Immunopathol. 39, 333\u2013337 (2017).","journal-title":"Semin. Immunopathol."},{"issue":"3","key":"88307_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.40397","volume":"70","author":"MD Richter","year":"2018","unstructured":"Richter, M. D. et al. Brief report: Cancer immunotherapy in patients with preexisting rheumatic disease: the mayo clinic experience. Arthritis Rheumatol. 70(3), 356\u2013360 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"88307_CR14","doi-asserted-by":"crossref","unstructured":"Haanen J, et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann. Oncol. (2020).","DOI":"10.1016\/j.annonc.2020.03.285"},{"issue":"2","key":"88307_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap): A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42(2), 377\u2013381 (2009).","journal-title":"J. Biomed. Inform."},{"issue":"9\u201310","key":"88307_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/0021-9681(84)90041-9","volume":"37","author":"EF Cook","year":"1984","unstructured":"Cook, E. F. et al. Empiric comparison of multivariate analytic techniques: Advantages and disadvantages of recursive partitioning analysis. J. Chronic. Dis. 37(9\u201310), 721\u2013731 (1984).","journal-title":"J. Chronic. Dis."},{"issue":"69","key":"88307_CR17","doi-asserted-by":"publisher","first-page":"114268","DOI":"10.18632\/oncotarget.23217","volume":"8","author":"A Diehl","year":"2017","unstructured":"Diehl, A. et al. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget 8(69), 114268\u2013114280 (2017).","journal-title":"Oncotarget"},{"key":"88307_CR18","doi-asserted-by":"crossref","unstructured":"Yarchoan M, et al. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 209\u201322 (2017).","DOI":"10.1038\/nrc.2016.154"},{"issue":"8","key":"88307_CR19","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","volume":"24","author":"A Pavan","year":"2019","unstructured":"Pavan, A. et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist. 24(8), 1128\u20131136 (2019).","journal-title":"Oncologist."},{"key":"88307_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","volume":"106","author":"SJ Bagley","year":"2017","unstructured":"Bagley, S. J. et al. Pretreatment neutrophil to lymphocyte ratio as a marker of outcomes in nivolumab treated patients with advanced non-small cell lung cancer. Lung Cancer 106, 1\u20137 (2017).","journal-title":"Lung Cancer"},{"issue":"9","key":"88307_CR21","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","volume":"69","author":"L Peng","year":"2020","unstructured":"Peng, L. et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitor. Cancer Immunol. Immunother. 69(9), 1813\u20131822 (2020).","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"88307_CR22","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1038\/bjc.2012.456","volume":"107","author":"T Kantola","year":"2012","unstructured":"Kantola, T. et al. Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br. J. Cancer. 107(10), 1729\u20131736 (2012).","journal-title":"Br. J. Cancer."},{"key":"88307_CR23","doi-asserted-by":"crossref","unstructured":"Cheng H, et al. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology 16(6), 1080\u20131084 (2016).","DOI":"10.1016\/j.pan.2016.09.007"},{"key":"88307_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cncr.31778","volume":"125","author":"MA Bilen","year":"2019","unstructured":"Bilen, M. A. et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer 125, 127\u2013134 (2019).","journal-title":"Cancer"},{"key":"88307_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.1252510","volume":"344","author":"RA Franklin","year":"2014","unstructured":"Franklin, R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science 344, 921\u2013925 (2014).","journal-title":"Science"},{"key":"88307_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc1256","volume":"4","author":"JW Pollard","year":"2004","unstructured":"Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71\u201378 (2004).","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"88307_CR27","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens, A. et al. Peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin. Cancer Res. 22(12), 2908\u20132918 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"88307_CR28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/art.24328","volume":"60","author":"K Hemminki","year":"2009","unstructured":"Hemminki, K. et al. Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. Arthritis Rheum. 60(3), 661\u2013668 (2009).","journal-title":"Arthritis Rheum."},{"key":"88307_CR29","first-page":"2227","volume":"33","author":"JM Anaya","year":"2006","unstructured":"Anaya, J. M. et al. Autoimmune disease aggregation in families with primary Sjo\u00a8gren\u2019s syndrome. J. Rheumatol. 33, 2227\u20132234 (2006).","journal-title":"J. Rheumatol."},{"key":"88307_CR30","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/rheumatology\/ken184","volume":"47","author":"K Sundquist","year":"2008","unstructured":"Sundquist, K. et al. Concordant and discordant associations between rheumatoid arthritis, systemic lupus erythematosus and ankylosing spondylitis based on all hospitalisations in Sweden between 1973 and 2004. Rheumatology (Oxford) 47, 1199\u20131202 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"88307_CR31","doi-asserted-by":"crossref","unstructured":"Alarcon-Segovia D, et al, on behalf of the Grupo Latinoamericano de Estudio del Lupus Eritematoso (GLADEL). Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 52, 1138\u201347 (2005).","DOI":"10.1002\/art.20999"},{"key":"88307_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","volume":"107","author":"O Hasan Ali","year":"2019","unstructured":"Hasan Ali, O. et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur. J. Cancer. 107, 8\u201314 (2019).","journal-title":"Eur. J. Cancer."},{"key":"88307_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos, F. X. et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur. J. Cancer. 91, 21\u201329 (2018).","journal-title":"Eur. J. Cancer."},{"issue":"6","key":"88307_CR34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-019-02321-z","volume":"68","author":"KL Kehl","year":"2019","unstructured":"Kehl, K. L. et al. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol. Immunother. 68(6), 917\u2013926 (2019).","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"88307_CR35","doi-asserted-by":"publisher","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","volume":"8","author":"J Haanen","year":"2020","unstructured":"Haanen, J. et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J. Immunother. Cancer. 8(1), e000604 (2020).","journal-title":"J. Immunother. Cancer."},{"issue":"2","key":"88307_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab, N. et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann. Intern. Med. 168(2), 121\u2013130 (2018).","journal-title":"Ann. Intern. Med."},{"key":"88307_CR37","doi-asserted-by":"crossref","unstructured":"Calabrese L, et al. Checkpoint immunotherapy: Good for cancer therapy, bad for rheumatic diseases. Ann. Rheum. Dis. 76, 1e3 (2017).","DOI":"10.1136\/annrheumdis-2016-209782"},{"key":"88307_CR38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies, A. M. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368\u2013376 (2017).","journal-title":"Ann. Oncol."},{"key":"88307_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234\u2013240 (2016).","journal-title":"JAMA Oncol."},{"key":"88307_CR40","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi, G. C. et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J. Clin. Oncol. 36, 1905\u20131912 (2018).","journal-title":"J. Clin. Oncol."},{"key":"88307_CR41","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"88307_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11523-020-00739-5","volume":"15","author":"LC Kennedy","year":"2020","unstructured":"Kennedy, L. C. et al. Untangling the multidisciplinary care web: Streamlining care through an immune-related adverse events (IRAE) tumor board. Target. Oncol. 15(4), 541\u2013548 (2020).","journal-title":"Target. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88307-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88307-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88307-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:28:53Z","timestamp":1670034533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88307-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88307"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88307-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-136849\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]},"assertion":[{"value":"27 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. D Michailidou has no disclosures. Dr. AR Khaki: owned stock from Merck and Sanofi within the last 3\u00a0years. Dr. MP Morelli has not disclosures. Dr. L Diamantopoulos has no disclosures. Dr. N Singh has no disclosures. Dr. P Grivas (all unrelated in the last 3\u00a0years): Consulting: AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dyania Health, Driver; EMD Serono; Exelixis; Foundation Medicine; Genentech\/Roche; Genzyme; GlaxoSmithKline; Heron Therapeutics; Immunomedics, Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; Seattle Genetics; QED Therapeutics. Research Funding to Institution: Merck; Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm, Bristol-Myers Squibb, QED Therapeutics, GlaxoSmithKline, Mirati Therapeutics, Kure It Cancer Research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9029"}}